AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03544450 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial counselling
Description: Individuals with psychological distress receive psychosocial counselling and enhanced usual care. The psychosocial the counselling process consists of: (i) introduction, explanation and rapport building; (ii) assessment of and understanding of the problem (including looking for positive assets); (iii) goal setting (asking the client what outcomes are preferred); (iv) problem management (exploring and identifying solutions, brainstorming, working with existing coping strategies, using social and cultural resources, and additional techniques such as relaxation and psycho-education); (v) implementation (making a plan of action and transition); and, finally, (vi) termination of counselling (including closing and follow-up). Enhanced usual care is provided by health workers, who have already been trained on diagnosis and treatment of common mental disorders, and usage of basic psychosocial counseling skills (communication, listening and basic emotional support).
Study NCT03544450 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Enhanced usual care is provided by health workers, who have already been trained on diagnosis and treatment of common mental disorders, and usage of basic psychosocial counseling skills (communication, listening and basic emotional support).
Study NCT03544450 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Usual Care
Description: Enhanced usual care is provided by health workers, who have already been trained on diagnosis and treatment of common mental disorders, and usage of basic psychosocial counseling skills (communication, listening and basic emotional support).
Study NCT01742884 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thealoz
Description: Instillation of 1 drop of Thealoz
Study NCT01742884 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: 1 drop of the vehicle will be instillated in the eye
Study NCT02001129 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Automated Telephone System
Description: Participants receive automated reminder phone calls.
Study NCT02001129 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Telephone Call
Description: Participants receive reminder phone calls by study staff.
Study NCT02001129 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Participants receive a standard reminder letter in the mail.
Study NCT02001129 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants receive a standard reminder letter in the mail.
Study NCT02663310 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery treatment of the injured vertebra(e), internal fixation of the vertebral column, and bilateral laminectomy for epidural decompression were followed directly by neurosurgical management, including separation of the arachnoid adhesion to restore cerebrospinal fluid flow and debridement of the spinal cord necrotic tissue with concomitant intramedullary decompression.
Study NCT02663310 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation
Description: The patients need to do intensive rehabilitation everyday. （1）The limb comprehensive training is Kunming Locomotor exercise, 60 minutes twice per day.(2)The exercise therapy includes sit-ups by 30 times, twice per day; half bridge exercise by 10 times, twice per day; backward flight movement by 10 times, twice per day; sling exercise training by 30 minutes, twice per day; and postural transfer functional training by 10 minutes, twice per day. (3)The balance training include ball toss training by 10 minutes, twice per day; and balance board training by 10 minutes, twice per day. (4)The wheelchair training will be taken 20 minutes each, twice per day. (5)The isokinetic training needs to perform 20 minutes each, twice per day.
Study NCT02663310 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: The patients need to do intensive rehabilitation everyday. （1）The limb comprehensive training is Kunming Locomotor exercise, 60 minutes twice per day.(2)The exercise therapy includes sit-ups by 30 times, twice per day; half bridge exercise by 10 times, twice per day; backward flight movement by 10 times, twice per day; sling exercise training by 30 minutes, twice per day; and postural transfer functional training by 10 minutes, twice per day. (3)The balance training include ball toss training by 10 minutes, twice per day; and balance board training by 10 minutes, twice per day. (4)The wheelchair training will be taken 20 minutes each, twice per day. (5)The isokinetic training needs to perform 20 minutes each, twice per day.
Study NCT03940716 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IntERact
Description: This intervention integrates motivational interviewing, cognitive behavioral skills therapy, and care management into a single behavioral counseling intervention delivered by a therapist. The intervention is delivered either in the emergency department or remotely over the subsequent 5 weeks for a total of six therapy sessions (\~30 min each). A smartphone app is also loaded on the participant's phone and delivers additional behavioral intervention content, including tailored MI+CBT messages (tailored by daily survey responses), one-touch pro-social contact encouragement, psycho-educational materials, GPS-enabled just-in-time tailored alerts, and facilitated access to care management resources.
Study NCT00437749 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CBT-1
Description: (50 mg caps) 500 mg/m2/day x 7 + paclitaxel 135 mg/m2 + carboplatin AUC 6
Study NCT00437749 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: (50 mg caps) 500 mg/m2/day x 7 + paclitaxel 135 mg/m2 + carboplatin AUC 6
Study NCT02432573 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delayed rounds
Study NCT03154021 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Next Science OTC Oral Rinse with Essential Oils
Description: This group will receive Next Science Oral Rinse with Essential Oils and the other half will be give OTC Oral Rinse Control
Study NCT03154021 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: OTC Oral Rinse Control
Description: This group will receive OTC Oral Rinse Control
Study NCT01931917 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incredible Years Parents and Babies Program
Description: 4-5 home visits by health visitor IY parents and babies program 8 sessions Group of mothers Health visitor station Extra visits by health visitor if needed
Study NCT01931917 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: 4-5 home visits by health visitor Group of mothers Health visitor station Extra visits by health visitor if needed
Study NCT02505425 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Support
Description: ENABLE CHF-PC includes:~1. In-person comprehensive Palliative Care Team (PCT) Consultation- as soon as feasible after enrollment.~2. Palliative Care Nurse Coach (PNC) embedded within HF teams, instituting a phone-based 6-session patient and a 4-session caregiver curriculum followed by monthly phone-based supportive care for 48 weeks or patient death.~The PNC uses the manualized curriculum: Charting Your Course (CYC): An Intervention for Patients with Heart Failure and their Families.~Usual Care: Usual heart failure care includes any available supportive care resources and heart failure patient medical management based on national HF guidelines.
Study NCT02505425 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual HF Care
Description: Usual heart failure care includes any available supportive care resources and heart failure patient medical management based on national HF guidelines.
Study NCT00994864 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: FOLFOX
Description: One cycle of standard FOLFOX pre-operatively followed by 11 cycles of standard adjuvant FOLFOX chemotherapy.
Study NCT04818905 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Helichrysum italicum infusion
Description: Active beverage or control beverage consumption after overnight fasting and calorimetry measurement on a single subject. After seven days washout period follows the consumption of the alternate beverage and measurements.
Study NCT04818905 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Hot water
Description: Active beverage or control beverage consumption after overnight fasting and calorimetry measurement on a single subject. After seven days washout period follows the consumption of the alternate beverage and measurements.
Study NCT01881815 — intervention group
Intervention type: OTHER
Intervention: Swabs
Description: There is no intervention only swabs are being used to collect wound fluid samples
Study NCT02598037 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Test meal
Description: The test meal will contain the following features: 50% carbohydrate, 20% protein and 30% of total fat, and will be admnistrada after drawing blood fasting for 12 hours.
Study NCT01193452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1, Leucovorin
Description: S-1 :~The initial dosage of S-1 is determined by the body surface area:~Surface area: 1.25-1.5 m2 : 50mg twice per day;upper than 1.5 m2 : 60mg twice per day~Leucovorin:~25mg twice per day po.~The treatment is given for one week,and no chemotherapy is given for the following one week.
Study NCT01193452 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leucovorin, 5-fluorouracil
Description: leucovorin: 400mg/m2 intravenous infusion d1;~5-fluorouracil: 400mg/m2 intravenous push,d1; 2400mg/m2 continuous intravenous infusion for 46 hours~repeat every 2 weeks
Study NCT03179917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: pembrolizumab 200mg IV will be given over 30 minutes on day 1 of each 21 day cycle for a total of 4 cycles. Pediatric patients will be treated at 2 mg/kg with a maximum dose of 200 mg.
Study NCT03179917 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Involved Site Radiation Therapy
Description: 30 Gy of ISRT
Study NCT02579031 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orsiro
Description: Novel biodegradable-polymer sirolimus-eluting stent used during primary percutaneous coronary intervention
Study NCT02579031 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xience
Description: Durable-polymer everolimus-eluting stent used during primary percutaneous coronary intervention
Study NCT02586597 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation & median nerve stimulation
Description: Paired associative stimulation (PAS) is a new technique where one pairs a peripheral stimulation with centrally applied transcranial magnetic stimulation (TMS), and produces plasticity, as measured by TMS MEP's. Currently PAS is performed with median nerve stimulation.~PA25: The interval between median nerve stimulation and TMS was chosen to be 25 ms, which is called PAS25. 240 paired TMS and median nerve stimulation at a frequency of 0.2 Hz over 20 min.~PAS10: 240 paired TMS and median nerve stimulation with interval of 10 min second at a frequency of 0.2 Hz over 20 min.~PAS100: 240 paired TMS and median nerve stimulation with interval of 100 min second at a frequency of 0.2 Hz over 20 min.
Study NCT00990587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclopirox Olamine
Description: Patients will take Ciclopirox Olamine at various doses depending on which dose level they come into the study at. Ciclopirox olamine will be administered orally as an aqueous suspension without food. The starting dose will be 5 mg/m2/day administered as a single dose daily for 5 days (one cycle). Once a MTD has been determined, the new patients that enter into the trial will then take it at that level.
Study NCT02487381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: delta-9-tetrahydrocannabinol
Study NCT02487381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Study NCT02586597 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial magnetic stimulation & median nerve stimulation
Description: Paired associative stimulation (PAS) is a new technique where one pairs a peripheral stimulation with centrally applied transcranial magnetic stimulation (TMS), and produces plasticity, as measured by TMS MEP's. Currently PAS is performed with median nerve stimulation.~PA25: The interval between median nerve stimulation and TMS was chosen to be 25 ms, which is called PAS25. 240 paired TMS and median nerve stimulation at a frequency of 0.2 Hz over 20 min.~PAS10: 240 paired TMS and median nerve stimulation with interval of 10 min second at a frequency of 0.2 Hz over 20 min.~PAS100: 240 paired TMS and median nerve stimulation with interval of 100 min second at a frequency of 0.2 Hz over 20 min.
Study NCT02866968 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FLAPS
Description: Surgical procedures will involve 1) excision of pterygium tissue from cornea and conjunctiva, 2) resection of residual Tenon and coagulation to stop any bleeding 3) preparation of a 8x8 mm conjunctiva autograft in the superior bulbar conjunctiva with the femtosecond laser (12 o´clock position) and 4) fixation of the graft with fibrin glue to the resection site.
Study NCT00151567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Description: Oral tamsulosin once a day until stone elimination or the end of the follow-up (42 days)
Study NCT03333356 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: pelvic radiotherapy
Description: adjuvant pelvic radiotherapy consisting of 28 x 1.8 Gy fractions (total dose of 50.4 Gy), 5 days per week, 1 fraction / day (duration of RT is 38 days).
Study NCT03212976 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Phase contrast magnetic resonance imaging
Description: Phase-contrast magnetic resonance imaging will be done to assess intracranial pressure
Study NCT02487381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02487381 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01583218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betrixaban
Description: Betrixaban 80 mg PO once daily (QD) for 35 day + 7 days.~Enoxaparin Placebo: Once daily, 6-14 days
Study NCT01583218 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Enoxaparin 40 mg subcutaneous (SC) QD for 10 ± 4 days.~Betrixaban Placebo: once daily, 35 days
Study NCT02610387 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS)
Description: Participants underwent tDCS(2mA) brain stimulation for 20 minutes plus balance training for 20 minutes for 5 consecutive days.
Study NCT02610387 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: During sham stimulation, the current ramped up for 30 seconds, ramped back down for 30 seconds, and then remained off for the duration of the stimulation plus balance training for 20 minutes for 5 consecutive days.
Study NCT03786133 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Analysis of microbiological tests
Description: Collection and comparison of microbiological data
Study NCT02149121 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT-P10
Description: 1000mg by intravenous infusion. 2 infusions with a 2-week interval between the first and second infusion
Study NCT00943761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaniprevir 600 mg b.i.d.
Description: Oral capsules containing 150 mg vaniprevir, four in the morning and four in the evening, for 48 weeks
Study NCT00943761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaniprevir 300 mg b.i.d.
Description: Oral capsules containing 150 mg vaniprevir, two in the morning and two in the evening, for 48 weeks
Study NCT00943761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon
Description: Prefilled syringe containing 180 µg/0.5 mL peg-IFN, for weekly subcutaneous injection, for 48 weeks
Study NCT00943761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Oral tablets containing 200 mg RBV, 5 or 6 tablets, dosage based on the participant's weight (\<75 kg or ≥75 kg, respectively), for 48 weeks
Study NCT01911468 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Study NCT01911468 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liraglutide
Study NCT02063919 — intervention group
Intervention type: OTHER
Intervention: the mucosal microbiome in the biopsy specimen was analysed
Study NCT01911468 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin and liraglutide
Study NCT02338388 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cesarean section technique
Description: Comparing three different types of suturing the uterus at Cesarea section
Study NCT04528797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine
Study NCT00693888 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: advice (e.g. medical and social aspects, care, support at home, residential advice, legal aspects, demonstration of help and support for the relatives)
Description: initial comprehensive assessment, stratified (city, suburbs) randomization into two groups: interventional group: individual comprehensive primary advice (medical and social aspects, care, support at home, residential advice, legal aspects, demonstration of help and support for the relatives), control group: standard support, observation over a period of 6 months, possibility of completing the diagnostic after final assessment
Study NCT01342926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK933776
Description: GSK933776
Study NCT01342926 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01337778 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Primary care for Daughters-in-Law
Description: Primary care for DILs will be offered based on national and international standards and include access to critical support services for women who have experienced GBV.A comprehensive health examination for MILs will include a gynecological exam and screening for diabetes and hypertension, along with appropriate information, prescriptions, and/or referrals. We will routinely offer GBV-related resources, such as information, counseling, and referrals to all participants. Referrals will be documented using a Referral Care Form and reviewed on a routine basis to ensure that appropriate care is being provided and to detect any potential study-related risks.
Study NCT01337778 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Dil Mil Intervention
Description: The Dil Mil intervention will be implemented during the second and third trimesters of the DILs' pregnancy. It consists of 2 half-day group sessions with DILs, 5 half-day group sessions with MILs, and one joint half-day session with DILs and MILs. The sessions are based on participatory learning and action principles and use stories, role-play, and discussion to enhance participants' knowledge, skills, and social support. Participants are encouraged to critically analyze their relationships and to develop and implement responses appropriate to their families and communities. The DIL-MIL joint session ends in a short celebration (based on a traditional ritual) in which MILs bless their DILs, and the MIL sessions culminate in a ceremony in which MILs' position in the family and community is recognized and celebrated. MILs draw up a family health action plan and take a pledge to reduce GBV and protect and promote their family's health.
Study NCT03382912 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegilodecakin
Description: Pegilodecakin plus Nivolumab
Study NCT03382912 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Nivolumab Alone
Study NCT03382912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab Alone
Study NCT04528797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Study NCT02637726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol : TCI Schnider
Description: Target controlled infusion using schnider model for propofol
Study NCT02637726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol : TCI Kataria
Description: Target controlled infusion using Kataria model for propofol
Study NCT02637726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol : TIVA
Description: Total intravenous anesthesia without use of a pharmokinetic model
Study NCT02637726 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG Monitoring
Description: Maintaining a bispectral index between 45 and 55
Study NCT00707473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT00707473 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy
Description: Undergo chemoradiotherapy
Study NCT00707473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT00707473 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Definitive Surgical Resection
Description: Undergo surgery
Study NCT00707473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV
Study NCT02637726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Remifentanil at discretion of the anesthesiologist